



# A Phase 2, Open-Label Study of Vobramitamab Duocarmazine in Participants with Metastatic Castration-Resistant Prostate Cancer and Other Solid Tumors (TAMARACK)

Status: Recruiting

## Eligibility Criteria

Sex: Male or Female

**Age Group:** 18 years and over This study is NOT accepting healthy

volunteers

### **Inclusion Criteria:**

- locally advanced or metastatic squamous cell carcinoma (SCC) of the anus, melanoma, head and neck squamous cell carcinoma (HNSCC), squamous non-small cell lung carcinoma (NSCLC), and small cell lung carcinoma (SCLC) - received at least 1 prior line of systemic therapy for unresectable or metastatic disease and no more than 2 prior lines of cytotoxic chemotherapy - participants with HNSCC or melanoma must have received prior PD-1 or PD-L1 inhibitor - women must not be pregnant, planning to be pregnant, or breastfeeding - see link to clinicaltrials.gov for complete inclusion and exclusion criteria

## **Exclusion Criteria:**

- untreated, symptomatic central nervous system (CNS) metastasis - prior stem cell, tissue, or solid organ transplant - another cancer that was treated in the past two years

## Conditions & Interventions

### Conditions:

Cancer

#### Keywords:

Clinics and Surgery Center (CSC), anal cancer, head and neck squamous cell carcinoma, HNSCC, melanoma, SCC, squamous cell carcinoma

## More Information

**Description:** The study drug is an antibody-drug conjugate (ADC). An ADC is an antibody with an anti-cancer drug attached. The antibody portion of the ADC brings the anti-cancer drug specifically to the cancer cell, where it will attach to a protein on the outside of the cancer cell. When the ADC attaches to the cancer cell, the anti-cancer drug passes into the cancer cell and damages the cancer cell leading to the death of the cancer cell. Since the antibody portion contains a target that is specific to cancer cells, this helps keep the anticancer drug from hurting normal cells.

Study Contact: Emmanuel Antonarakis - anton401@umn.edu

Principal Investigator: Manish Patel

IRB

Number: SITE00001784

Thank you for choosing StudyFinder. Please visit http://studyfinder.umn.edu to find a Study which is right for you and contact sfinder@umn.edu if you have questions or need assistance.